• 2 More New England Compounding Center Drugs Linked to Meningitis Outbreak
  • October 18, 2012 | Authors: Mark P. Chalos; Heather A. Foster
  • Law Firm: Lieff, Cabraser, Heimann & Bernstein, LLP - San Francisco Office
  • The Food and Drug Administration ("FDA") said Monday that two additional drugs may be linked to the multistate fungal meningitis outbreak stemming from steroid injections made by a compounding pharmacy in Massachusetts. A cooling solution made by the New England Compounding Center ("NECC") called cardioplegia, used in heart surgery, and a second injected steroid called triamcinolone acetonide now may be involved in the outbreak. That finding is based on its investigation, along with inquiries by the Centers for Disease Control and Prevention and by state health departments.

    The triamcinolone injection made by NECC was linked to one case of possible meningitis, the FDA said. It didn't give the location of the new case.The agency also said two heart-transplant patients recently became infected with Aspergillus fumigatus, the fungus involved in a minority of the recent meningitis cases, though the agency didn't say the patients contracted meningitis. The agency, which didn't give locations of the cases, also said that "there may be other explanations for their Aspergillus infection."

    For nearly two weeks, the meningitis cases identified so far by federal officials were linked with injections of methylprednisolone acetate. A total of 15 states have reported cases of meningitis, with 212 people sickened. Fifteen people have died.